

Collaborative Working Project executive summary

Project title	A collaborative working project between Sanofi and Liverpool Place within Cheshire & Mersey ICB to deliver a targeted quality improvement and population health management programme to transform how patients with Chronic Obstructive Pulmonary Disease (COPD) are identified, treated, and supported.
Partner organisation/s	<p>NHS Cheshire & Mersey ICB No.1 Lakeside, 920 Centre Park Square, Warrington, WA1 1QY</p> <p>NHS Liverpool Place Cunard Building, 2nd Floor, Water St, Liverpool L3 1AH</p> <p>Sanofi, 410 Thames Valley Drive, Reading, Berkshire, RG6 1PT</p>
Project rationale	<p>Current Situation and Challenges:</p> <p>Regional Performance:</p> <ul style="list-style-type: none"> Cheshire and Merseyside ICB rank 42nd out of 42 ICBs in England for respiratory outcomes Second-highest rate of respiratory admissions (915 per 100,000) Second-highest rate of respiratory deaths (122.9 per 100,000) <p>COPD Prevalence and Diagnosis:</p> <ul style="list-style-type: none"> 70,192 people diagnosed with COPD in Cheshire & Mersey ICB (March 2024) 2.4% increase (1,644 new diagnoses) since March 2023 Liverpool's COPD prevalence is 3.6% (18,306 people), nearly double the England average of 1.9% Estimated 4,381 people with undiagnosed COPD in Liverpool Up to 27% of COPD diagnoses in Liverpool may be incorrect <p>Healthcare System Strain:</p> <ul style="list-style-type: none"> COPD is the leading reason for readmissions (25% within 30 days) Highest number of additional respiratory patient interactions in the country Limited access to diagnostic tests worsening patient experience and outcomes <p>Health Inequalities:</p> <ul style="list-style-type: none"> 8-year life expectancy gap between most and least deprived areas Liverpool is the 3rd most deprived local authority in the UK 63% of Liverpool residents live in areas ranked among the most deprived in England 31,188 households in Liverpool face fuel poverty or poor housing conditions Up to 50% of people with 'Complex Lives' in Liverpool have COPD

	<p>Project Aim: To transform COPD identification, treatment, and support within Cheshire and Merseyside ICB, starting with a focused pilot in Liverpool. The project aims to improve patient outcomes, reduce avoidable hospital admissions, and optimise resource utilisation.</p> <p>Scope and Objectives:</p> <ol style="list-style-type: none"> Comprehensive COPD Pathway Review: <ul style="list-style-type: none"> Assess alignment with NICE guidelines and national priorities Benchmark against national comparators (NRAP, GIRFT Review, Model Health System) Engage NHS stakeholders to map current pathway and identify gaps Develop evidence-based improvement recommendations Population Health Analysis: <ul style="list-style-type: none"> Analyse A&E attendances, hospital admissions, and follow-up care Review uptake of preventative interventions (vaccinations, pulmonary rehabilitation, smoking cessation, etc.) Identify areas of unexpectedly low COPD prevalence for targeted screening Assess alignment with Core20PLUS5 objectives Wider Respiratory Needs Assessment: <ul style="list-style-type: none"> Examine community respiratory service adequacy for other conditions Improve Patient Identification and Risk Stratification: <ul style="list-style-type: none"> Enhance methods for identifying high-risk patients Prioritise ongoing specialist care and early intervention Maximize Efficiency and Introduce Innovation: <ul style="list-style-type: none"> Identify opportunities for better resource allocation Explore requirements for advanced COPD therapies Support understanding of neighbourhood model needs for respiratory services Deliver Actionable Recommendations: <ul style="list-style-type: none"> Develop prioritised options to improve pathways, service delivery, and access Create an outline Action Plan and Evaluation Framework <p>Future Expansion - Phase Two:</p> <ul style="list-style-type: none"> Target patients "lost in the system" Focus on neighbourhoods with highest COPD-related health inequalities <p>Expected Benefits:</p> <ol style="list-style-type: none"> Clinical Outcomes: <ul style="list-style-type: none"> Earlier, accurate COPD diagnosis (potential 15.7% reduction in treatment costs)
--	--

	<ul style="list-style-type: none"> • Reduced hospital admissions and readmissions • Improved patient experience and quality of life <p>2. System Improvements:</p> <ul style="list-style-type: none"> • Close gaps in care and follow-up • Increase uptake of proven preventative measures • Reduce unwarranted variation in treatment • Better alignment with national guidelines and priorities <p>3. Resource Optimisation:</p> <ul style="list-style-type: none"> • Target resources to areas of greatest need • Improve service efficiency <p>4. Health Equity:</p> <ul style="list-style-type: none"> • Address health inequalities in line with Core20PLUS5 objectives • Targeted interventions for deprived areas and complex patients <p>5. Scalability:</p> <ul style="list-style-type: none"> • Provide a blueprint for system-wide respiratory improvement • Potential for expansion across Cheshire and Merseyside
Project period	<p>Start date: Q4 2025</p> <p>End date Q3, 2026</p>
Project objectives	<p>The collaborative working project will undertake a review of the COPD pathway and service and develop a report with recommendations to improve the pathway and service for patients with COPD.</p> <p>This will inform an action plan to implement agreed changes which has the potential to deliver the following benefits for Patients, the NHS and Sanofi:</p> <p><u>Patients</u></p> <ul style="list-style-type: none"> • To ensure equity of pathway access, provision, and experience for patients with COPD in Liverpool, part of Cheshire & Mersey ICB. • Quicker and more equitable access to care for patients with COPD. • Better access to treatment options for patients with COPD as well as a clear pathway of care with an improved patient experience. <p><u>NHS</u></p> <ul style="list-style-type: none"> • Improved pathway for patients with COPD. • Reduction in unwarranted variations in care for patients with COPD through targeting the programme at areas of high deprivation. • Increase in patients with COPD receiving specialist review in a timely manner through improved

	<p>identification and referral from primary care and follow-up and treatment optimisation after A&E attendance and hospital admission.</p> <ul style="list-style-type: none"> • Improving the identification of patients at high risk of hospital admission and readmission. • Implementation of an improved and more efficient pathway for patients with COPD that is in line with NICE guidance and ensuring high value fundamentals of COPD care are consistently provided. • Learning from the implementation of a population health management approach for patients with COPD that can inform the implementation of population health management in other disease areas/population groups • By specifically targeting areas of high deprivation the approach in COPD could potentially be transposed to other disease areas. • Optimisation of the solutions that are already in place. <p><u>Sanofi</u></p> <ul style="list-style-type: none"> • A better understanding of the COPD services within Cheshire & Mersey ICB and Liverpool Place. • Improved corporate reputation with Cheshire & Mersey ICB and Liverpool Place and partner organisations by supporting them to improve the quality of care for patients with COPD. • Understanding of how a population health management approach can be used to improve patient care. • As a result of pathway changes some appropriate patients in the future may be prescribed Sanofi products in line with NICE guidance. <p>Total project costs is £14,000 52% NHS vs 48% Sanofi contribution</p>
Contact details	<p>Liverpool Place, NHS Cheshire & Mersey ICB</p> <p>Amanda Brookes, Liverpool Place, Delivery Manager, Liverpool place, NHS Cheshire & Mersey ICB</p> <p>Sanofi</p> <p>Paul Naish, Head of Market Access</p> <p>GB-marketaccess@sanofi.com</p>